PMID- 28079268
OWN - NLM
STAT- MEDLINE
DCOM- 20170710
LR  - 20170713
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
VI  - 44
IP  - 4
DP  - 2017 Apr
TI  - Renoprotective effect of Hypericum perforatum against diabetic nephropathy in 
      rats: Insights in the underlying mechanisms.
PG  - 509-521
LID - 10.1111/1440-1681.12729 [doi]
AB  - Oxidative stress and inflammation play a key role in the initiation and 
      progression of diabetic nephropathy (DN). The present study aimed to investigate 
      the possible protective effect of hypericum perforatum (HP) against DN. Rats were 
      allocated into six groups: control, received normal saline; diabetic untreated 
      (DM), received single dose of streptozotocin (STZ) after injection of 
      nicotinamide (NA); gliclazide, received STZ,NA + gliclazide (10 mg/kg); 
      DM + HP50, DM + HP100, DM + HP200, received STZ,NA and HP 50, 100, 200 mg/kg, 
      respectively. Gliclazide and HP were administered daily via gavage for 8 weeks. 
      Serum glucose, insulin, kidney function and histopathological picture were 
      assessed. Furthermore, oxidative/nitrosative stress, inflammatory cytokines, 
      apoptotic and fibrotic markers were measured. Diabetic untreated group showed 
      increase in serum glucose, urea, creatinine with albuminurea. Renal expression of 
      protein for nuclear factor kappa-B (NF-small ka, CyrillicB), renal expression of inducible nitric 
      oxide synthase (iNOS), cyclooxygenase II (COXII), collagen IV, fibronectin were 
      elevated. Malondialdehyde (MDA), nitric oxide (NO), tumour necrosis factor-alpha 
      (TNF-alpha), interleukin-1beta (IL-1beta), intracellular adhesion molecule (ICAM-1), 
      monocellular chemoattractant protein-1 (MCP-1), tumour growth factor- beta (TGF-beta), 
      caspase-3 and cytochrome c contents were also increased consequently with decline 
      of serum insulin, expression of peroxisome proliferator-activated receptor 
      (PPARgamma), renal reduced glutathione (GSH) content and superoxide dismutase (SOD) 
      activity. Treatment with either gliclazide or HP mitigated the deleterious 
      effects of STZ on the tested parameters. These findings indicate for the first 
      time that HP may have a renoprotective effect against DN through reduction of 
      oxidative/nitrosative stress, enhancement of antioxidant defense mechanisms, 
      decline of inflammatory cytokines, antifibrotic, antiapoptotic and blood glucose 
      lowering properties.
CI  - (c) 2017 John Wiley & Sons Australia, Ltd.
FAU - Abd El Motteleb, Dalia M
AU  - Abd El Motteleb DM
AUID- ORCID: 0000-0002-4379-6323
AD  - Department of Pharmacology, Faculty of Medicine, Zagazig University, Zagazig, 
      Egypt.
FAU - Abd El Aleem, Dalia I
AU  - Abd El Aleem DI
AD  - Department of Medical Physiology, Faculty of Medicine, Zagazig University, 
      Zagazig, Egypt.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (Antioxidants)
RN  - 0 (Collagen Type IV)
RN  - 0 (Fibronectins)
RN  - 0 (Inflammation Mediators)
RN  - 0 (NF-kappa B)
RN  - 0 (PPAR gamma)
RN  - 0 (Transforming Growth Factor beta)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - G4PX8C4HKV (Gliclazide)
SB  - IM
MH  - Animals
MH  - Antioxidants/metabolism
MH  - Apoptosis/drug effects
MH  - Body Weight/drug effects
MH  - Collagen Type IV/metabolism
MH  - Cyclooxygenase 2/metabolism
MH  - *Cytoprotection/drug effects
MH  - Diabetic Nephropathies/*metabolism/*pathology
MH  - Fibronectins/metabolism
MH  - Gene Expression Regulation, Enzymologic/drug effects
MH  - Gliclazide/pharmacology
MH  - Hypericum/*physiology
MH  - Inflammation Mediators/metabolism
MH  - Kidney/drug effects/metabolism/*pathology
MH  - Male
MH  - NF-kappa B/metabolism
MH  - Nitric Oxide Synthase Type II/metabolism
MH  - Oxidative Stress/drug effects
MH  - PPAR gamma/metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Transforming Growth Factor beta/metabolism
OTO - NOTNLM
OT  - hypericum perforatum
OT  - NF-small ka, CyrillicB
OT  - PPAR gamma
OT  - TGF-beta
OT  - diabetic nephropathy
OT  - gliclazide
OT  - oxidative stress
EDAT- 2017/01/13 06:00
MHDA- 2017/07/14 06:00
CRDT- 2017/01/13 06:00
PHST- 2016/05/21 00:00 [received]
PHST- 2016/12/30 00:00 [revised]
PHST- 2017/01/04 00:00 [accepted]
PHST- 2017/01/13 06:00 [pubmed]
PHST- 2017/07/14 06:00 [medline]
PHST- 2017/01/13 06:00 [entrez]
AID - 10.1111/1440-1681.12729 [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2017 Apr;44(4):509-521. doi: 10.1111/1440-1681.12729.